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Burkholderia pseudomallei, the causative agent of melioidosis, encodes almost a dozen predicted polyketide (PK) biosynthetic gene clusters. Many
of these are regulated by LuxR-I-type acyl-homoserine (AHL) quorum-sensing systems. One of the PK gene clusters, the mal gene cluster, is conserved in the
close relative Burkholderia thailandensis. The B. thailandensis mal genes code for
the cytotoxin malleilactone and are regulated by a genetically linked LuxR-type
transcription factor, MalR. Although AHLs typically interact with LuxR-type proteins to modulate gene transcription, the B. thailandensis MalR does not appear
to be an AHL receptor. Here, we characterize the mal genes and MalR in B. pseudomallei. We use chemical analyses to demonstrate that the B. pseudomallei mal
genes code for malleilactone. Our results show that MalR and the mal genes
contribute to the ability of B. pseudomallei to kill Caenorhabditis elegans. In B.
thailandensis, antibiotics like trimethoprim can activate MalR by driving transcription of the mal genes, and we demonstrate that some of the same antibiotics induce expression of B. pseudomallei malR. We also demonstrate that B. pseudomallei MalR does not respond directly to AHLs. Our results suggest that MalR
is indirectly repressed by AHLs, possibly through a repressor, ScmR. We further
show that malleilactone is a B. pseudomallei virulence factor and provide the
foundation for understanding how malleilactone contributes to the pathology of
melioidosis infections.
IMPORTANCE Many bacterially produced polyketides are cytotoxic to mammalian

cells and are potentially important contributors to pathogenesis during infection. We
are interested in the polyketide gene clusters present in Burkholderia pseudomallei,
which causes the often-fatal human disease melioidosis. Using knowledge gained by
studies in the close relative Burkholderia thailandensis, we show that one of the B.
pseudomallei polyketide biosynthetic clusters produces a cytotoxic polyketide, malleilactone. Malleilactone contributes to B. pseudomallei virulence in a Caenorhabditis elegans infection model and is regulated by an orphan LuxR family quorum-sensing
transcription factor, MalR. Our studies demonstrate that malleilactone biosynthesis or
MalR could be new targets for developing therapeutics to treat melioidosis.
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urkholderia pseudomallei is the causative agent of melioidosis, an often fatal and
difﬁcult to treat condition estimated to be responsible for ⬃90,000 deaths worldwide per year (about 40% of total infections) (1). Despite the severity and worldwide
incidence of melioidosis, the basic biology and pathogenesis mechanisms of this
species remain relatively poorly understood, in part because of the difﬁculty of handling it in the laboratory. Because B. pseudomallei poses a high risk to national security
and public health, it is considered a tier 1 select agent and, as such, requires biosafety
level 3 (BSL3) safety conditions for handling. Due to this restriction, much knowledge
of B. pseudomallei stems from studies conducted on a close relative, Burkholderia
thailandensis, which is safe for handling in BSL2 laboratory conditions. B. thailandensis
and B. pseudomallei have a high degree of genetic relatedness and share about 85% of
their genes. Species are differentiated by some metabolic capabilities, species-speciﬁc
genes (including virulence genes in B. pseudomallei), and four large-scale (⬎10 kb)
genomic inversions (2, 3). In addition to B. thailandensis, two B. pseudomallei attenuated
strains were recently excluded from select agent regulations (4, 5) and thus can be used
in BSL2 laboratory conditions. These strains provide new opportunities to study B.
pseudomallei directly.
We are interested in understanding the pathogenic mechanisms of B. pseudomallei,
particularly those mediated by small-molecule toxins, which are emerging as an
important contributor to B. pseudomallei virulence in mammalian infections (6, 7). A
substantial portion of the B. pseudomallei genome is dedicated to polyketide (PK) and
nonribosomal peptide (NRP) secondary metabolism, with almost a dozen predicted
PK/NRP gene clusters (6). Some of these gene clusters are also present in B. thailandensis, which has been used as a surrogate in some cases (8–10). Some of the clusters
have been studied directly in B. pseudomallei, particularly those that are not shared in
B. thailandensis (6, 7, 11–13). In many cases, no polyketide products, or very low
concentrations, are synthesized in standard laboratory conditions, making them difﬁcult to identify and study. In some cases, the products can be generated by using a
genetic approach of synthetically inducing transcription of the biosynthetic genes (6, 8,
14). In others, speciﬁc laboratory conditions can trigger production (9, 15).
Many predicted secondary metabolite gene clusters in B. pseudomallei are regulated
by acyl-homoserine lactone (AHL) quorum sensing (16, 17). These systems typically
involve luxI-luxR gene pairs that code for signal synthase and receptor proteins,
respectively. In some cases, luxR genes are not linked to any luxI genes, and these are
called orphans or solos (18, 19). Many LuxR orphans are AHL responsive; however, at
least some appear to be signal independent (20, 21). In B. pseudomallei, there are three
LuxR-LuxI signaling systems, BpsR1-I1, BpsR2-I2, and BpsR3-I3. There are also two
orphans, MalR (also called BpsR4) and BpsR5. MalR in B. thailandensis has been shown
to control production of malleilactone (20), the product of a PK/NRP gene cluster and
a cytotoxin that contributes to B. thailandensis virulence in nematodes (8). At least in B.
thailandensis, MalR appears to be an unusual LuxR orphan, in that it is not a receptor
for AHLs (20).
In this study, we focus on the malleilactone (mal) biosynthetic genes in B. pseudomallei, and speciﬁcally on the products and regulation of the mal cluster. The protein
products of the mal biosynthetic genes and malR share ⬃80% identity in B. thailandensis and B. pseudomallei. The mal genes are silent in B. thailandensis under standard
laboratory conditions. Expression of the mal cluster seems to be induced by certain
antibiotics, including several used to treat melioidosis infections. Induction is through
increased expression of malR. Here, we use knowledge gained from studies of the B.
thailandensis mal genes to guide studies in B. pseudomallei. We demonstrate that the
product of the B. pseudomallei genes is also malleilactone and that malleilactone
contributes to B. pseudomallei virulence, as it does in B. thailandensis. The results of this
work provide new information on small-molecule biosynthesis and regulation in B.
pseudomallei and the biology of this understudied pathogen.
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FIG 1 B. pseudomallei mal genes code for production of malleilactone. (A) The mal gene clusters from B. pseudomallei (Bp), B. thailandensis (Bt),
and B. mallei (Bm), with predicted function of each encoded protein. Shading indicates percent identity to the B. pseudomallei protein sequences.
White, 100%; light gray, 90 to 99%; dark gray, 80 to 89%; black, ⬍80%. (B) Production of a malleilactone-like product in B. pseudomallei cultures.
Levels of malleilactone production in the wild type (WT), ΔmalF strain, and WT grown with 4.5 g/ml trimethoprim (Tp) are shown. (C) Proposed
B. pseudomallei malleilactone structure consistent with liquid chromatography-mass spectrometry approach (LC-MS)/MS and nuclear magnetic
resonance (NMR) results.

RESULTS
The B. pseudomallei mal genes code for malleilactone biosynthesis. The B.
thailandensis malleilactone (mal) biosynthetic genes are in an ⬃35-kb region that is also
present in B. pseudomallei and B. mallei (Fig. 1A). The predicted proteins encoded by
this cluster share ⬃80 to 90% amino acid identity in all three species. The genomic
organization of this region is also well conserved, with the exception of two genes
coding for hypothetical proteins (MalBa and MalBb) which are found in B. pseudomallei
and B. mallei but not in B. thailandensis. The product of the mal genes in B. thailandensis
is malleilactone. Based on the sequence conservation among these three species, we
predicted that the B. pseudomallei mal gene product might be similar or identical to
malleilactone. To test this prediction, we deleted the B. pseudomallei malF gene that is
required for B. thailandensis malleilactone production (8). We compared the secondary
metabolic proﬁle of the B. pseudomallei malF mutant with that of the parental wild-type
strain (Bp82) using a high-resolution liquid chromatography-mass spectrometry approach (HR-LC-MS). In the B. pseudomallei Bp82 culture, we observed a relatively small
peak corresponding to the molecular weight of B. thailandensis malleilactone, which
was absent in malF mutant cultures (Fig. 1B).
Under standard conditions, B. pseudomallei produced limited quantities of the
presumed malleilactone product, which precluded further studies to characterize the
structure of this compound. In B. thailandensis, malleilactone production is triggered by
subinhibitory concentrations (below the MIC) of the antibiotic trimethoprim (15, 20).
Thus, we grew B. pseudomallei cells with 4.5 g/ml trimethoprim, a concentration that
slowed growth by about 25%. Cells grown with this trimethoprim concentration
produced ⬃5-fold-higher titers of the presumed malleilactone compound than did
July 2018 Volume 200 Issue 14 e00008-18
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TABLE 1 Ability of antibiotics to activate PmalA-lacZ in B. pseudomallei
Growth inhibitor (g/ml)a
None
Trimethoprim (15)
Sulfamethoxazole (500)
Ceftazidime (1.75)
Piperacillin (10)
Ciproﬂoxacin (1)
Imipenem (1.7)
Polymyxin B (600–700)
Kanamycin (150)
Paraquat (500–700 nM)d

Antibiotic mechanism
THF pathway inhibitorc
THF pathway inhibitor
Cell wall synthesis inhibitor
Cell wall synthesis inhibitor
DNA gyrase inhibitor
Cell wall synthesis inhibitor
Membrane permeabilization
30S ribosome inhibitor
Reactive oxygen stress

Relative PmalA-lacZ activityb
1
10.7 (⫾0.4)
10.5 (⫾3.1)
4.9 (⫾0.7)
4.7 (⫾1.1)
4.1 (⫾0.8)
1.8 (⫾0.2)
1.4 (⫾0.1)
0.9 (⫾0.1)
1.3 (⫾0.1)

aThe

untreated cells (Fig. 1B). Thus, we used trimethoprim as an inducer to generate
sufﬁcient quantities for further characterization. We initially characterized the product
using a tandem HR-MS (HR-MS/MS) approach. The HR-MS/MS fragmentation pattern of
the B. pseudomallei malleilactone-like product was consistent with that of B. thailandensis malleilactone (Fig. 1C; see also Fig. S1 in the supplemental material). We also
puriﬁed the product and conducted structural analysis by nuclear magnetic resonance
spectroscopy (NMR). We used a puriﬁcation procedure similar to that reported previously for B. thailandensis (20), with an important modiﬁcation. We found that compound stability during and after puriﬁcation was signiﬁcantly improved by using a
neutral pH in the mobile-phase buffer during secondary puriﬁcation (pH 6.5) (see
Materials and Methods). Our NMR data agreed well with those published for B.
thailandensis-produced malleilactone (8, 14) (see Fig. S2 and Table S2 in the supplemental material). Together, our results demonstrate that the product of the B. pseudomallei mal genes is malleilactone, and that malleilactone production is enhanced
during growth with trimethoprim.
Antibiotic activation of the B. pseudomallei mal genes. Trimethoprim is an
inhibitor of the tetrahydrofolate biosynthesis pathway. Several antibiotics with other
cellular targets also induce B. thailandensis mal gene expression, including ﬂuoroquinolone DNA gyrase inhibitors and the cell wall biosynthesis inhibitors piperacillin and
ceftazidime (15). These antibiotics activate mal gene expression at concentrations that
slow growth. However, slowed growth is not sufﬁcient to induce the mal cluster, as
some antibiotics such as the ribosome inhibitor kanamycin do not induce B. thailandensis mal gene expression. We were interested in identifying which antibiotics can
induce expression of the mal genes in B. pseudomallei. To identify mal-inducing
antibiotics, we constructed a reporter strain by fusing a promoterless lacZ gene to the
promoter of malA, the ﬁrst gene in the mal gene cluster, and introducing this reporter
into the glmS3 site in the B. pseudomallei genome. We tested a variety of antibiotics at
sublethal but growth-slowing concentrations. Our results show that trimethoprim
induces the PmalA-lacZ reporter (Table 1), consistent with our mass spectrometry
results (Fig. 1B). B. pseudomallei mal genes were also induced by antibiotics other than
trimethoprim, such as sulfamethoxazole (which inhibits the tetrahydrofolate biosynthetic pathway, similarly to trimethoprim), and, to a lesser extent, ciproﬂoxacin (a
ﬂuoroquinolone), ceftazidime, and piperacillin. It is of note that trimethoprim, sulfamethoxazole, and ceftazidime are used clinically to treat melioidosis, although it is unclear
whether this ﬁnding has any importance in vivo. Three antibiotics, namely, kanamycin,
polymyxin B (an outer membrane-integrity disruptor), and imipenem (a ␤-lactam), did
not activate expression of the mal genes.
July 2018 Volume 200 Issue 14 e00008-18
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concentration of antibiotic used is indicated in parentheses, and in each case this concentration
resulted in about 50 to 70% reduction of growth yield as determined by the optical density at 600 nm
(OD600) measured at the time of ␤-galactosidase measurement, compared with that of an identically grown
untreated culture.
bGrowth-adjusted ␤-galactosidase activity is given relative to that of the untreated control. ␤-Galactosidase
activity and optical density at 600 nm (OD600) were determined after 24 h. Values are the mean of at least
three independent experiments, with the statistical range of the median indicated in parentheses.
cTHF, tetrahydrofolate reductase.
dParaquat generates oxidative stress through superoxide production.

Journal of Bacteriology

Because some antibiotics trigger induction of oxidative stress response pathways
through production of reactive oxygen species (22), we wondered if induction of
oxidative stress could lead to activation of mal gene expression. Thus, we tested
whether Paraquat (1,1=-dimethyl-4,4=-bipyridinium dichloride), which induces oxidative
stress through the production of superoxide, can induce mal gene expression. We
tested Paraquat at concentrations that slow growth, and our results showed that
Paraquat did not induce the mal gene cluster, consistent with the idea that mal gene
expression is not induced by oxidative stress. Instead, our results suggest that a variety
of antibiotics with different cellular targets can induce expression of the B. pseudomallei
mal biosynthetic genes. Some of the same antibiotics also induce the B. thailandensis
mal genes, suggesting a similar mechanism of antibiotic-dependent mal gene regulation in both species.
Malleilactone cytotoxicity and B. pseudomallei virulence. Previously, malleilactone was shown to be cytotoxic to several bacteria and to mammalian cells (8). Thus,
we assessed the toxicity of our malleilactone preparation. We tested the concentration
of malleilactone required to cause a 50% decrease in the viability of cultured human
A549 bronchial epithelial cells and human Jurkat T lymphocyte cells after 48 h in culture
(IC50). The IC50 of malleilactone was found to be 7.4 g/ml (24 M) for the A549 cell line
and 2.5 g/ml (8 M) for the Jurkat cell line (Fig. S3). This IC50 is comparable with those
previously reported for malleilactone against other mammalian cells (8). We also
determined the MIC of malleilactone against several bacterial species. Malleilactone
was cytotoxic to some Gram-positive bacterial species, including Staphylococcus aureus,
at concentrations ranging from 5 to 20 g/ml (18 to 70 M) (see Table S1 in the
supplemental material).
The cytotoxicity of malleilactone suggests that it might function as a virulence factor
in B. pseudomallei. We used a Caenorhabditis elegans infection model to test whether
malleilactone contributes to B. pseudomallei virulence. Previous studies indicate that B.
pseudomallei rapidly kills C. elegans through production of several secreted toxins,
although only one has been identiﬁed (11, 23–26). Toxins also appear to be a signiﬁcant
contributor to B. pseudomallei pathogenicity in mammalian infections (6, 7). We tested
the virulence of our malF biosynthesis mutant and a strain with a deletion in malR. MalR
is an orphan LuxR and is encoded adjacent to the mal biosynthesis genes. The B.
thailandensis MalR is important for C. elegans infections (8) and has been shown to be
a mal gene regulator (20) (Fig. 1A). For our virulence assays, we placed C. elegans worms
on a lawn of B. pseudomallei cells on nematode growth medium supplemented with
adenine and thiamine and monitored worm survival daily. Under these conditions, the
attenuated B. pseudomallei Bp82 strain was able to kill C. elegans worms within about
3 days (Fig. 2). C. elegans worms on Bp82 lawns also showed slowed movement and
were reproduction deﬁcient, as they produced fewer eggs than identically treated
nematodes that were fed nonpathogenic Escherichia coli. Thus, similar to ﬁndings for
virulent B. pseudomallei strains (23, 25, 26), our results demonstrate that Bp82 was able
to kill C. elegans in the presence of adenine and thiamine in the growth medium.
Compared with Bp82, the malF and malR mutants were slower to kill C. elegans under
identical growth conditions (Fig. 2). These results support the notion that malleilactone
production and the putative regulator MalR are important for B. pseudomallei virulence.
Induction of the mal genes relies on MalR and sufﬁcient malR expression. MalR
appears to be a key mal gene regulator in B. thailandensis, and our C. elegans infection
results indicate that MalR is also important in B. pseudomallei. To test whether B.
pseudomallei MalR regulates the mal genes, we introduced a short-half-life PmalAluxCDABE reporter into the neutral glmS3 site in the genome of our malR mutant and
the Bp82 parent and monitored reporter induction in each strain grown with or without
trimethoprim. Not surprisingly, we observed little to no PmalA-luxCDABE reporter
induction in either strain grown without trimethoprim (Fig. 3) At 15 g/ml (a concentration that reduced the growth yield by 50% at 24 h), trimethoprim activated the Bp82
reporter by about 6-fold, with maximal induction at 8 to 10 h (Fig. 3). However, there
July 2018 Volume 200 Issue 14 e00008-18
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was no trimethoprim-dependent reporter induction in malR mutant cells, showing that
MalR is important for trimethoprim activation of mal gene transcription. In B. thailandensis, MalR is not activated by trimethoprim directly, but rather the antibiotic increases
MalR activity by driving malR transcription. We tested whether trimethoprim similarly
increases B. pseudomallei malR transcription by using quantitative droplet digital PCR.
Our results show that trimethoprim increases B. pseudomallei malR transcription 4-fold
(see Fig. S4 in the supplemental material), consistent with the idea that trimethoprim
activates B. pseudomallei MalR indirectly by driving malR transcription.
Our results suggest that MalR activity correlates with the level of malR expression.
We sought to more directly test this hypothesis. We constructed an isopropyl-␤-Dthiogalactopyranoside (IPTG)-inducible malR expression cassette by fusing malR to the
Plac promoter and moved this cassette into the neutral glmS3 site in the genome of our
malR mutant. We measured malleilactone production in this Plac-malR-containing
strain and also in the malR mutant and Bp82 parent strains containing the empty Plac
cassette (Fig. 4). Consistent with our previous results (Fig. 1B and 2), malleilactone was
relatively low in the Plac-labeled Bp82 and even lower in the malR mutant. However,
the malR mutant containing Plac-malR had malleilactone levels that exceeded those
produced by Bp82 by more than 7-fold (P ⬍ 0.015). Thus, malR expression is sufﬁcient
to induce malleilactone production to high levels, even in the absence of trimethoprim.
Malleilactone production is repressed by N-3-hydroxy-octanoyl homoserine
lactone and N-3-hydroxy-decanoyl homoserine lactone. Results with B. thailandensis
indicate that MalR is not a typical LuxR family protein, in that it is not an AHL receptor.
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FIG 3 MalR is required for trimethoprim-dependent expression of malA in B. pseudomallei. Shown is the
growth-adjusted activity of a PmalA-luxBCABE chromosomal reporter in the malR mutant or its isogenic
parent, Bp82 WT, grown with 15 g/ml trimethoprim (Tp) or without trimethoprim. Results are the means
and standard errors from three independent experiments.
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FIG 2 Malleilactone contributes to B. pseudomallei killing of C. elegans. Death of C. elegans over time
when placed on a lawn of B. pseudomallei Bp82 WT, Bp82 ΔmalF, or Bp82 ΔmalR or E. coli OP50 cells. In
the case of E. coli, generation of new offspring prevented survival counts after day 3. Results are from one
experiment with 30 worms on each strain, but they are representative of similar experiments done on
separate days. The data were plotted using GraphPad Prism software, which generated survival fraction
calculations (Kaplan-Meier limit method) and analyzed the data (log rank Mantel-Cox test). By this
analysis, the median survival of each mutant is statistically different from that of the Bp82 parent (median
survival is 3 days for ΔmalF and ΔmalR strains and 1 day for WT; P ⬍ 0.0001).
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Previous studies with recombinant E. coli showed that B. thailandensis MalR activation
of the malA promoter is not inﬂuenced, either positively or negatively, by AHLs (20).
MalR proteins in B. pseudomallei and B. thailandensis differ by only 5 amino acids. Some
of these changes could possibly affect the ability of MalR to respond to AHLs. Thus, we
engineered plasmids to test B. pseudomallei MalR activity in recombinant E. coli. We
used a plasmid with an arabinose-inducible B. pseudomallei malR and another plasmid
containing a 1,000-bp fragment containing the B. pseudomallei malA promoter (from
positions ⫺1 to ⫺1000 with respect to the predicted MalA translational start site) fused
to a promoterless lacZ gene. In E. coli, lacZ activation required arabinose induction of
B. pseudomallei MalR and was not inﬂuenced by any of the AHLs tested (see Fig. S5 in
the supplemental material), including the B. pseudomallei AHLs N-octanoyl homoserine
lactone (C8-HSL), N-3-hydroxy-octanoyl homoserine lactone (3OHC8-HSL) and N-3hydroxy-decanoyl homoserine lactone (3OHC10-HSL).
Our results indicate that B. pseudomallei MalR does not interact with AHLs directly.
However, activation of the mal genes might be regulated by AHLs through other
indirect mechanisms. To test this possibility, we used a B. pseudomallei mutant with
deletions in all three of the AHL synthase genes (bpsI1, bpsI2, and bpsI3). We compared
malleilactone produced by this strain with that of the wild type. In our experiments, the
AHL mutant showed ⬃10-fold higher malleilactone than the Bp82 parent (Fig. 5A).
Malleilactone levels were restored to wild-type levels by exogenously adding all three
of the B. pseudomallei-produced AHLs to the growth medium (5 M each). When added
individually, 3OHC8-HSL, and to a lesser extent 3OHC10-HSL, repressed malleilactone
production but C8-HSL did not.
How does quorum sensing repress malleilactone production? Based on our previous
results, MalR is a likely candidate for indirect regulation by AHLs. In support of this idea,
introducing a malR deletion to the AHL synthase mutant reduced malleilactone to
almost undetectable levels (Fig. 5A). We hypothesized that AHLs regulate MalR indirectly by repressing malR expression. To test this hypothesis, we assessed malR expression in the triple AHL mutant and wild-type parent throughout growth. We also
assessed malR expression in the AHL mutant with 3OHC8-HSL added to the culture
medium. We sampled cells at three culture optical densities, namely, 2 (the transition
between logarithmic and stationary phase), 4 (stationary phrase), and 6 (stationary
phase). For all three strains, malR expression was relatively low until the culture reached
an optical density of 6. At this density, malR levels were almost 2-fold higher in the AHL
mutant compared with those of the wild type, and more than 3-fold higher in the AHL
mutant compared with those of the mutant grown with AHLs (P ⬍ 0.05) (Fig. 5B). We
also assessed malA expression in these cells. Our results showed that the pattern of
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FIG 4 Expression of lac promoter-controlled malR is sufﬁcient for malleilactone production in B. pseudomallei. Cells were grown with isopropyl-␤-D-thiogalactopyranoside (IPTG) to induce malR expression,
and cultures were collected at stationary phase (24 h), extracted with ethyl acetate, and assessed for
relative malleilactone, as described in Materials and Methods. Data shown are the growth-adjusted peak
areas corresponding with malleilactone at 370 nm (the malleilactone max). WT, Bp82 with the Plac
cassette; MalR⫺, Bp82 ΔmalR with the Plac cassette; MalR⫺ ⫹ MalR, Bp82 ΔmalR with the Plac-malR
cassette. All cultures were grown with 1 mM IPTG. Results are the means and standard errors from three
independent experiments. *, statistical signiﬁcance by t test (P ⬍ 0.015), compared with both WT and
MalR⫺.
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FIG 5 AHL-dependent regulation of malleilactone biosynthesis. (A) Cultures were collected during
stationary phase (24 h), extracted with ethyl acetate, and assessed for relative malleilactone, as described
in Materials and Methods. Data shown are the growth-adjusted peak areas corresponding with malleilactone at 370 nm (the malleilactone max). WT, Bp82; AHL⫺, Bp82 with deletions in all three of the AHL
synthase genes (bpsI1 to -3) (CM139); AHLs, 5 M (each or individually, as indicated) C8-HSL, 3OHC8-HSL,
and 3OHC10-HSL; AHL⫺ MalR⫺, Bp82 with deletions of bpsI1 to -3 and malR. (B and C) AHL-dependent
regulation of malR (B) and malA (C) transcription in Bp82 WT, AHL⫺ cells, and AHL⫺ cells with 5 M
3OHC8-HSL added to the culture medium. Transcript abundance was normalized to the rpoD RNA
polymerase sigma factor gene transcripts. In all cases, results are the means and standard errors from
three independent experiments. *, statistical signiﬁcance by t test compared with the wild type (P ⱕ
0.05).

malA expression was similar to that of malR, with maximal induction at a culture optical
density of 6 (Fig. 5C). These results are consistent with the idea that malR transcription
is induced in the AHL mutant, causing subsequent induction of the malleilactone
biosynthesis genes. Our results suggest that malR expression is repressed by AHLs very
late in growth. It is possible that other mechanisms repress malR at lower culture
densities.
Malleilactone production is repressed by a quorum sensing-activated regulator, ScmR. The B. pseudomallei AHL-responsive regulators BpsR1, BpsR2, and BpsR3
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FIG 6 Regulation and activity of B. pseudomallei ScmR. (A) Cultures were collected during stationary
phase (24 h), extracted with ethyl acetate, and assessed for relative malleilactone, as described in
Materials and Methods. Data shown are the growth-adjusted peak areas corresponding with malleilactone at 370 nm (the malleilactone max). WT, Bp82 with the Plac cassette inserted into the glmS3 site in
the genome; ScmR⫺, Bp82 glmS3::Plac with a deletion in scmR; ScmR⫺ ⫹ ScmR, Bp82 with Plac-scmR
inserted into glmS3; ScmR,⫺ MalR⫺, Bp82 glmS3::Plac with deletions in scmR and malR. (B) AHLdependent regulation of scmR transcription. WT, Bp82; AHL⫺, Bp82 with deletions in all three of the AHL
synthase genes (bpsI1 to -3) (CM139); AHL⫺ ⫹ 3OHC8-HSL, CM139 with 5 M 3OHC8-HSL added to the
culture medium. (C) ScmR-dependent regulation of malR transcription. Strains are described in the panel
A legend. Transcript abundance (B and C) was normalized to the rpoD RNA polymerase sigma factor gene
transcripts. Strains in panels A and C were grown with 1 mM IPTG. In all cases, results are the means and
standard errors from three independent experiments. *, statistical signiﬁcance by t test (P ⱕ 0.05).

typically function as gene promoter activators (27–30); thus, we hypothesized that
quorum sensing represses malR indirectly through another regulator. A likely candidate
is the putative transcriptional regulator ScmR. In B. thailandensis, ScmR is a quorum
sensing-activated repressor of malleilactone production and other secondary metabolites (31). The B. pseudomallei and B. thailandensis ScmR proteins are 99% identical. To
test the role of B. pseudomallei ScmR in malleilactone production, we deleted scmR in
Bp82 and compared malleilactone produced by the scmR mutant to that of the parent.
Our results showed that deleting scmR increased malleilactone production almost
4-fold (Fig. 6A) (P ⬍ 0.01). We were able to restore malleilactone production in the scmR
mutant to that of the wild type by expressing scmR from the IPTG-inducible Plac
promoter (Fig. 6A). To test whether B. pseudomallei quorum sensing activates scmR
transcription, we measured scmR transcripts in our triple AHL mutant, the wild-type
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DISCUSSION
The mal gene cluster is well conserved in B. thailandensis, B. pseudomallei, and also
B. mallei (⬃80% identity). These three species also share a high degree of genetic
similarity. Yet, they each have a distinctly different lifestyle. B. thailandensis is a
saprophyte, B. pseudomallei is an opportunistic pathogen, and B. mallei is a hostrestricted pathogen that causes a disease called glanders. We are interested in studying
this group because it provides a unique opportunity to understand how homologous
systems adapt to different lifestyles. The ﬁnding that the malleilactone biosynthesis
cluster is conserved in all three species suggests that it is important for diverse
lifestyles. In a saprophytic lifestyle, malleilactone might be important for competition
with other strains or species of bacteria. Malleilactone is also important for virulence in
an animal host (Fig. 2) (8). There is evidence from recent transposon sequencing
(Tn-seq) studies that malleilactone contributes to pathogenesis in mouse models of
melioidosis (32, 33). These studies use pools of B. pseudomallei transposon mutant
populations to infect the lungs of mice, and in these studies, insertions in malR, malA,
and some of the other mal biosynthetic genes reduced ﬁtness in the mouse lung and
spleen (e.g., malA mutants were 3-fold and 39-fold reduced in mouse lungs and spleen,
respectively) (32, 33). The exact role of malleilactone in B. pseudomallei ﬁtness during
infections in vivo remains to be determined.
The regulatory circuits controlling malleilactone production appear to be well
conserved in B. pseudomallei and B. thailandensis. The B. pseudomallei mal genes are
induced by at least some of the same antibiotics as the B. thailandensis mal genes, such
as trimethoprim, piperacillin, ceftazidime, and ciproﬂoxacin (15, 20) (Table 1). Furthermore, the mal genes in both species are not induced by kanamycin (15, 20) (Table 1).
These results suggest that the pathway of antibiotic-dependent regulation of the mal
genes might be conserved in these two species. Quorum-sensing repression of mal
gene expression is also similar in B. thailandensis and B. pseudomallei. In B. pseudomallei,
malleilactone production is repressed by 3OHC8-HSL and 3OHC10-HSL (Fig. 5A). These
AHLs are speciﬁc to the BpsR2-I2 system (27). This system is conserved in B. thailandensis, where it also represses malleilactone production (31). However, this system is
missing from the B. mallei genome. Instead, in B. mallei the mal genes appear to be
controlled by the C8-HSL-responsive system BmaR1-I1 (homologous to BpsR1-I1) (17).
Despite the potential variation in which system controls malleilactone production, the
conservation of quorum control of malleilactone production across these three species
suggests an important association with cell density that is broadly beneﬁcial in this
group.
Our results show that ScmR represses malleilactone production in B. pseudomallei.
They support a model whereby BpsR2-I2 activates production of the ScmR repressor
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parent, and the AHL mutant supplemented with 3OHC8-HSL. We found that scmR
transcripts were 3-fold lower in the AHL mutant than in wild-type cells (P ⬍ 0.01)
(Fig. 6B), suggesting that B. pseudomallei scmR transcription is controlled by quorum
sensing. We also assessed the importance of MalR in ScmR-dependent regulation of
malleilactone production. MalR is required for induction of malleilactone in the scmR
mutant, because deleting malR in the scmR mutant nearly abolished malleilactone
production (Fig. 6A). We hypothesized that ScmR might repress malleilactone production by decreasing malR transcription. To test this hypothesis, we measured malR
transcripts in an scmR mutant and compared these with those of the wild type at
culture optical densities of 2, 4, and 6. In support of our hypothesis, malR transcripts
were 2-fold higher in the scmR mutant compared with those of identically grown
wild-type cells during later growth (P ⬍ 0.05) (Fig. 6C), a pattern consistent with that
of malR expression in the AHL synthase mutant (Fig. 5B). Together, our results support
the idea that malleilactone production is controlled by quorum sensing indirectly
through ScmR, and that ScmR acts by repressing transcription of malR, thereby explaining why little to no malleilactone is produced under standard laboratory conditions.
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during later stages of growth, and ScmR decreases malleilactone production by repressing transcription of malR (Fig. 6). ScmR also represses malleilactone production in
B. thailandensis; however, in B. thailandensis ScmR was not shown to repress malR
during late log phase (31). It is possible that malR that repression also occurs in B.
thailandensis but only in late stationary phase, as it does in B. pseudomallei (Fig. 6).
Alternatively, this result might represent a difference in the regulatory circuits of B.
thailandensis and B. pseudomallei. The ﬁnding that ScmR represses malleilactone in B.
pseudomallei suggests that ScmR might function as a global repressor of B. pseudomallei secondary metabolism, as it does in B. thailandensis. ScmR is also conserved in B.
mallei, the causative agent of the disease glanders, and might be a useful target for
eliciting production of other secondary metabolites in the B. pseudomallei-group
pathogens. As some ScmR-dependent secondary metabolites are implicated in virulence (31), ScmR might also serve as a target for development of novel antivirulence
therapeutics to treat melioidosis and glanders.
Our results show that B. pseudomallei malleilactone is structurally identical to that of
B. thailandensis and corroborate previous studies showing that malleilactone is cytotoxic to both cultured mammalian cells and several kinds of Gram-positive bacteria. In
our experiments, B. thailandensis and B. pseudomallei were relatively insensitive to
malleilactone (MIC ⬎ 200 g/ml) (Table S1). Previously, we showed that B. thailandensis
growth is slowed by about 50% when 10 to 15 g/ml of malleilactone is added to
culture ﬂasks (20). These results suggest that B. thailandensis, and possibly other
bacterial species, is sensitive to malleilactone under certain conditions. In addition to
cytotoxicity, malleilactone could also have another role as an iron-chelating molecule
that binds or possibly imports iron. The butyrolactone core of malleilactone has the
potential to coordinate metal ions, and malleilactone has been shown to weakly
interact with iron (8). Furthermore, the mal genes are transcriptionally induced during
growth in low iron (34), suggesting a possible link to extracellular iron levels (35).
MATERIALS AND METHODS
Bacterial strains, culture conditions, and reagents. All bacterial strains, plasmids, and primers used
in this study are listed in Tables S3 to S5 in the supplemental material. We used B. pseudomallei strain
Bp82 (4), a select agent-excluded ΔpurM derivative of the fully virulent strain 1026b. Bp82 is an adenine
and thiamine auxotroph. We refer to Bp82 as wild-type B. pseudomallei. We used E. coli strains DH5␣ and
DH10B (Invitrogen) for genetic manipulations and strain BW27783 (36), which constitutively expresses
the arabinose transporter, for recombinant E. coli experiments. Bacteria were grown in Luria-Bertani (LB)
broth (10 g tryptone, 5 g yeast extract, and 5 g NaCl per liter) supplemented with 50 mM morpholinepropanesulfonic acid (MOPS) where indicated, or in M9 minimal medium supplemented with 0.4%
glucose and 10 mM para-chloro-phenylalanine (p-Cl-Phe; Sigma) for B. pseudomallei counterselection
during mutant construction. All B. pseudomallei growth media were supplemented with 1.6 mM adenine
hemisulfate and 0.005% thiamine HCl, with the exception of LB agar plates, which were not supplemented. All growth was at 37°C with shaking at 250 rpm, with the exception of C. elegans infection
assays, which were at 20°C (see below). Acyl-homoserine lactones were purchased from Sigma-Aldrich
and Caymen Chemicals, stored in ethyl acetate acidiﬁed with 0.1 ml/liter glacial acetic acid, and added
to empty culture tubes and dried down prior to addition of bacterial cultures. When appropriate, the
following antibiotics were used (per ml): 15 g (E. coli) and 100 g (B. pseudomallei) gentamicin, 100 g
ampicillin (E. coli), 50 g (E. coli) and 1 mg (B. pseudomallei) kanamycin, and 25 g (E. coli) and 2 mg (B.
pseudomallei) zeocin. We added 1 mM isopropyl-␤-D-thiogalactopyranoside (IPTG) as indicated.
We assayed ␤-galactosidase activity by using a Tropix Galacto-Light Plus chemiluminescence kit
according to the manufacturer’s protocol (Applied Biosystems, Foster City, CA). In all cases,
␤-galactosidase activity is reported as light units relative to the optical density at 600 nm (OD600).
Genomic DNA, PCR and DNA fragments, and plasmid DNA were puriﬁed by using a Puregene Core A kit,
plasmid puriﬁcation miniprep kit, or PCR cleanup/gel extraction kits (Qiagen or IBI-MidSci) according to
the manufacturer’s protocol.
Genetic manipulations. Unmarked, in-frame deletions of malR, malF, and scmR were constructed
using previously described methods (37). Brieﬂy, DNA fragments containing ⬃500 to 1,000 bp of DNA
ﬂanking each gene were generated by PCR or DNA synthesis (Genscript, New Jersey) and fused together
to create an unmarked, nonpolar deletion of each gene with incorporated HindIII and XbaI sites. These
fragments were digested with HindIII and XbaI and cloned into HindIII- and XbaI-digested pEX18KmpheS, which was transformed into Bp82 by electroporation. Merodiploids were selected on LB agar
containing kanamycin, and deletion mutants were counterselected on M9 agar with p-Cl-Phe. Mutant
strains were veriﬁed by testing for kanamycin sensitivity and by PCR-amplifying the deletion region and
sequencing the PCR product. The pUC18miniTn7T derivatives were introduced by electroporation into B.
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pseudomallei strains with the helper plasmid pTNS3, as previously described (38). We used PCR to verify
insertion into the attn7 site near glmS3, as previously described (38).
For recombinant malR expression in E. coli, malR was ampliﬁed from genomic DNA isolated from B.
pseudomallei Bp82 by using primers that incorporated restriction sites (EcoRI and XmaI) into the product.
The amplicon was cut with EcoRI and XmaI and ligated to EcoRI- and XmaI-digested pJN105 to make
pJN105 PBAD-malR. To generate a lacZ fusion to the malA promoter for recombinant E. coli experiments,
the region upstream of B. pseudomallei malA extending from positions ⫺1 to ⫺476 with respect to the
translational start site was synthesized (Genscript, New Jersey), with restriction sites (NcoI and HindIII)
incorporated into the product. The G block was digested with NcoI and HindIII and ligated to NcoI- and
HindIII-digested pQF50 to make pQF50 PmalA-lacZ. To make the Plac-malR expression cassette, we ﬁrst
constructed the IPTG-inducible expression vector pUC18-mini-Tn7T-Km-Plac by digesting the kanamycin
(Km) resistance gene from pUC18-mini-Tn7T-Km-FRT (38) with SalI and NsiI and using this fragment to
replace the trimethoprim (Tp) resistance gene in SalI-NsiI-digested pUC18-min-Tn7T-LAC-Tp (20) to make
pUC18-mini-Tn7T-LAC-Km. We then cloned malR into this vector by PCR-amplifying malR from the Bp82
genome using primers that incorporated restriction sites (SacI and HindIII) into the product. The
amplicon was cut with SacI and HindIII and ligated into SacI- and HindIII-digested pUC18-mini-Tn7TKm-Plac to generate pUC18-mini-Tn7T-Km-Plac-malR. The Plac-scmR expression cassette was made by
introducing an EcoRI-HindIII-cut scmR PCR-generated amplicon to the EcoRI-HindIII-cut pUC18-miniTn7T-Km Plac-malR. To make the pUC18-mini-Tn7T-Zeo-PmalA-lux reporter plasmid, the B. pseudomallei
malA promoter region from bp ⫺1 to ⫺1,244 with respect to the translational start site was ampliﬁed
from Bp82 genomic DNA using primers that incorporated BamHI and PstI. The fragment was digested
with BamHI and PstI and then ligated into BamHI- and PstI-digested plasmid pCM53 (promoterless
lux reporter plasmid) (39). To make the pUC18-mini-Tn7T-Zeo-PmalA-lacZ reporter plasmid, we ﬁrst
constructed a pUC18-mini-Tn7T-Zeo-PmalA-GFP intermediate plasmid. This was done by PCRamplifying the GFP gene from pUC18-mini-Tn7T-Kan-GFP (40) and incorporating restriction sites PstI
and SpeI, PCR-amplifying the promoter and open reading frame of the zeocin resistance gene (ble)
from pUC18-mini-Tn7T-Zeo-PmalA-lux and incorporating restriction sites SpeI and StuI, and ligating
both of those fragments into PstI- and StuI-digested pUC18-mini-Tn7T-Zeo-PmalA-lux (releasing the
luxCDABE cassette and the ble gene). Then, the lacZ gene was subcloned from the pUC18-miniTn7T-Gm-lacZ plasmid (41) by digesting with AseI, treating with Klenow (New England BioLabs) to
blunt-end the fragment, and then digestion with PstI. The lacZ was ligated to pUC18-mini-Tn7TZeo-PmalA-GFP plasmid digested with SpeI, Klenow-treated, and then digested with PstI (to remove
the GFP gene) to generate pUC18-mini-Tn7T-Zeo-PmalA-lacZ. In all cases, constructs generated
using PCR were veriﬁed by sequencing.
HR-LC-MS measurements. For measuring malleilactone in B. pseudomallei cultures, samples were
prepared by diluting stationary-phase B. pseudomallei cultures to an OD600 of 0.05 into 50 ml of LB-MOPS
in a 250-ml ﬂask, and growing cultures for 24 h with 250 rpm shaking at 37°C. B. pseudomallei growth
media was supplemented with adenine and thiamine, and, where indicated, cultures were also supplemented with trimethoprim at 4.5 g/ml, IPTG at 1 mM, or synthetic AHLs at 5 M each. Each culture was
extracted with an equivalent volume of ethyl acetate, and the organic phase was collected using a
separatory funnel. The organic phase was then dried down under nitrogen air and suspended in 300 l
dimethyl sulfoxide (DMSO) plus 1,300 l acetonitrile. Subsequent dilutions in acetonitrile were then
performed as needed. Injections of 2 l each were made on nm Acquity ultraperformance liquid
chromatography (UPLC) system (Waters) with a wash of 500 l acetonitrile and 800 l of water/methanol
(1:1) between each injection. The UPLC was coupled to a photodiode array detector and an LCT Premier
TOF mass spectrometer (Waters), and the system was ﬁtted with an Acquity C18 ethylene bridged hybrid
(BEH) column (2.1 ⫻ 50 mm, 1.7 m; Waters). The chromatography was developed using an aqueous
mobile phase with NH4OH at pH 9.8 and an organic phase of acetonitrile increased by a gradient of 5%
to 99% over 2.7 min and then held at 99% acetonitrile for 0.4 min; the ﬂow rate was 0.6 ml/min. Relative
malleilactone was reported as the growth-adjusted total area under the 370 nm peak corresponding with
malleilactone (the max of malleilactone is 373 nm). In all cases, fragments were monitored using mass
spectrometry to validate the molecular weight of malleilactone in the expected peak.
Mass spectral data were collected by negative ion electrospray from 100 to 1,100 m/z, with capillary
set to 2,500 V, desolvation gas set to 300°C, and cone set to 35 V. Relative malleilactone was reported
using the peak area at 370 nm, the max of malleilactone. For LC-MS/MS experiments, negative ion
electrospray spectra were acquired on a Waters Qtof Premier (Waters/Micromass, Manchester, UK) mass
spectrometer operated in v mode at a resolution of 10,000. Spectra were acquired over the mass range
50 to 1,000 u, accumulating data for 3 s per cycle. LC-MS/MS spectra were simultaneously collected using
collision-induced dissociation (CID), using an MS1 quadrupole set to transmit the precursor mass (m/z
305.1), with a selection window of 4 u. The collision energy was ramped from 15 to 45 eV per acquisition
cycle to obtain a distribution of fragments from low to high mass. Product ions in the CID spectra ranged
from the same mass to 2 mmu and the relative abundances of CID fragments ranged from the same to
better than 5%.
B. pseudomallei malleilactone puriﬁcation and analysis. Samples for malleilactone puriﬁcation
were grown and ethyl acetate extracted as described for mass spectrometry analysis, except growth was
in 650 ml of media with 4.5 g/ml trimethoprim in a 1.6-liter ﬂask, and the dried ethyl acetate extract
was reconstituted in 10 ml acetonitrile. For comparison, B. thailandensis cultures were grown similarly
except with 15 g/ml trimethoprim and no adenine or thiamine added to the growth media. For
malleilactone puriﬁcation, two separate rounds of chromatography were performed on a Waters
autopuriﬁcation system equipped with a Waters 996 photodiode array (PDA), a 2525 binary pump, a 2767
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sample manager, a Waters ZQ single quad mass spectrometer, and a Waters XBridge C18 column (5 m,
19 by 150 mm). For the ﬁrst round of chromatography, injections of 1,200 l each were made using an
aqueous mobile phase with NH4OH at pH 9.8 and an organic phase of acetonitrile which increased by
a gradient from 25% to 45% over 4 min, followed by a hold at 100% for 2 min; the ﬂow rate was 20
l/min. The fractions were pooled and evaporated using a Genevac instrument at 35°C, and the residue
was reconstituted in 10 ml of acetonitrile. For the second round of chromatography, injections of 1,200
l each were made using an aqueous mobile phase with 20 mM NH4HCOO at pH 7.0 and an organic
mobile phase of acetonitrile with a gradient of 35% to 55% over 4 min, followed by a hold at 100% for
2 min. Fractions were triggered by UV at 370 nm and mass at 305 m/z with a mass spectrometer set to
negative ionization, with the capillary at 2.9 kV, the source at 100°C, and the cone at 50 V. Final fractions
were pooled and evaporated under a stream of N2 gas and stored dry at ⫺20°C. For NMR characterization, puriﬁed malleilactone was dissolved in CDCl3 (Cambridge Isotopes) and transferred to a 5-mm tube
(Wilmad-LabGlass). All NMR spectra were acquired on a 500 MHz AVIII spectrometer (Bruker) equipped
with a cryogenically cooled broadband observe probe. Data were processed and visualized using
Topspin (Bruker) and MestReNova (Mestrelab) software.
Malleilactone susceptibility experiments. The MICs of malleilactone against bacterial pathogens
were determined using a protocol adapted from the 2003 guidelines of the Clinical and Laboratory
Standards Institute (CLSI, formerly NCCLS), using the microtiter MIC method. Inocula for each test
organism were prepared by suspending a colony from an LB agar plate into tryptic soy broth and
growing for 3 to 5 h at 35°C with shaking, then adjusting the culture turbidity in phosphate-buffered
saline (PBS) to the equivalent of a 1.0 McFarland standard (3 ⫻ 108 CFU/ml). These cell suspensions were
used as inocula for microtiter MIC assays. Inocula (2.5 l), which each corresponded to 1 ⫻ 106 cells, was
added to 100 l wells, each containing malleilactone diluted in cation-adjusted Mueller-Hinton II broth,
and these were incubated with shaking for 24 h at 37°C. The MIC was deﬁned as the lowest concentration
of malleilactone (in micrograms per milliliter) in which bacterial growth in the well was not measurable
by determining the turbidity at 600 nm (A600) on a BioTek Synergy 2 plate reader.
Malleilactone cytotoxicity experiments. The minimum concentration causing 50% loss of viability
(IC50) of malleilactone against cultured A549 and Jurkat cells was measured using propidium iodide
staining and ﬂow cytometry (42). Brieﬂy, A549 cells (ATCC CCL-185) were cultured in Dulbecco’s modiﬁed
Eagle medium (DMEM) (D6429; Sigma). Jurkat cells (ATCC TIB-152) were cultured in RPMI 1640 medium
(R8758; Sigma). Media was supplemented with fetal bovine serum (FBS; 10%), penicillin (100 units/ml),
and streptomycin (100 g/ml). Cells were maintained in a humidiﬁed 5% CO2 incubator at 37°C. A 96-well
microtiter plate was seeded with 8,000 cells in 200 l medium per well and grown at 37°C for 16 h. Cells
were then treated with fresh medium containing concentrations of malleilactone ranging from 10⫺12 to
10⫺4 M. After incubation at 37 °C for 48 h, adherent A549 cells were washed with phosphate-buffered
saline (pH 7.4) and suspended by treatment with trypsin-EDTA solution (50 l) for 10 min at 37°C,
followed by addition of propidium iodide (3 M ﬁnal concentration) in complete medium (100 l). For
Jurkat cells in suspension, propidium iodide (2 l, 3 M ﬁnal concentration) was added directly to the
medium. Viable cells were quantiﬁed by light scattering and exclusion of propidium iodide using a
CytoFLEX ﬂow cytometer. The data from 3 replicates were used to generate a dose-responsive curve.
These curves were ﬁtted by nonlinear regression with an inhibitor versus response variable-slope
4-parameter model (GraphPad Prism 7) to determine the concentration that causes 50% loss of viability
(IC50) values.
C. elegans infections. To assess the contributions of MalR and malleilactone genes in B. pseudomallei
virulence, we used a Caenorhabditis elegans infection model using the N2 Bristol wild-type C. elegans
strain. C. elegans were cultured at 20°C on solid nematode growth medium (NGM; 3 g NaCl, 2.5 g Bacto
peptone, 17 g Bacto agar, 5 g cholesterol, 1 mM [each] CaCl2 and MgSO4, and 1 mM KPO4 buffer [pH
6.0] per liter), and the E. coli strain OP50 was used as the C. elegans food source. When C. elegans worms
cultured on B. pseudomallei strain cultures, 3.2 mM adenine and 0.010% thiamine were added to the NGM
plates. For infection assays, overnight cultures of B. pseudomallei or the E. coli OP50 food source were
diluted to an OD600 of 0.1, 30 to 40 l were spread onto the center of the NGM plates, and the plates
were incubated overnight at 37°C. Plates were acclimated to room temperature for ⬃1 h prior to seeding
the plates with C. elegans (10 late larval [L4]-staged worms per plate). Survival of the worms was
monitored every 24 h until all worms were dead or until generation of new offspring prevented survival
counts (in the case of E. coli). Of note, in every case, few to no deaths of OP50-fed worms were observed,
and very few offspring were ever generated by worms that were fed B. pseudomallei.
Droplet digital PCR. RNA was harvested from B. pseudomallei cells at the indicated durations or
optical densities, using methods described previously (43). Droplet digital PCR was performed on QX200
droplet digital PCR (ddPCR) (Bio-Rad) system using EvaGreen Supermix. Each reaction mixture contained
0.25 to 0.5 ng of cDNA template, 900 nM each primer, and 10 ul EvaGreen Supermix in a 20-l ﬁnal
volume. After generating 40 l of oil droplets, 40 rounds of PCR were conducted using the following
cycling conditions: 95°C for 30 s, 58°C for 30 s, and 68°C for 30 s. Absolute transcript levels were
determined using QuantaSoft software (Bio-Rad). In all cases, a no-template control reaction was
performed, which contained no detectable transcripts. The rpoD RNA polymerase sigma factor gene was
used as a reference gene unless otherwise noted, and the results are reported as the calculated transcript
amount of a given gene per calculated rpoD transcript.
Transcription reporter assays. To assess MalR activation of malA in B. pseudomallei, we used a B.
pseudomallei strain with either a PmalA-lacZ or a PmalA-luxCDABE fusion cassette introduced to the
neutral glmS3 site in the chromosome (see Table S3 in the supplemental material). Logarithmic-phase
cultures were diluted to an OD600 of 0.05 in LB broth supplemented with antibiotics at the concentrations
July 2018 Volume 200 Issue 14 e00008-18
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indicated. Reporter activity was determined by measuring ␤-galactosidase activity as described above or
by direct luminescence measurements on a BioTek Synergy 2 plate reader.

SUPPLEMENTAL MATERIAL
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SUPPLEMENTAL FILE 1, PDF ﬁle, 0.9 MB.
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